Trials / Completed
CompletedNCT06212960
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
Double-blind, Randomized, Parallel Design, Active-controlled Phase 1 Clinical Trial to Evaluate the Efficacy and Safety of DWP712 and Botox® in Adult Patients in Need of Moderate to Severe Glabellar Lines
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DWP712 | Clostridium botulinum Toxin |
| BIOLOGICAL | BOTOX® | Clostridium botulinum Toxin |
Timeline
- Start date
- 2023-11-28
- Primary completion
- 2024-02-26
- Completion
- 2024-03-21
- First posted
- 2024-01-19
- Last updated
- 2024-04-04
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06212960. Inclusion in this directory is not an endorsement.